46th Annual Meeting of the European Association for the Study of the Liver (EASL 2011)

March 30 - April 3, 2011, Berlin, Germany

Back EASL 2011

Coverage of the 46th Annual Meeting of the European Association for the Study of the Liver

March 30 - April 3, 2011, Berlin, Germany

The material posted on HIVandHepatitis.com is not approved by nor is it a part of EASL 2011.

Hepatitis C Articles

Hepatitis B Articles

Library of Slides and Posters

EASL Releases New Hepatitis C Clinical Practice Guidelines

EASL updates European guidelines for management of patients with acute and chronic hepatitis C virus (HCV) infection. alt

Read more:

EASL 2011: HIV/HCV Coinfection among HIV Positive Gay Men

Researchers at EASL presented further data on outbreaks of sexually transmitted HCV among HIV positive men who have sex with men. Sustained response rates are high when interferon-based therapy is started during acute infection, but re-infection after treatment is common in this population. alt

Read more:

EASL 2011: Boosted ABT-450 Improves Early Response to Interferon for Hepatitis C

Addition of the experimental HCV protease inhibitor ABT-450, boosted with ritonavir, to standard therapy increased the likelihood of complete early virological response at 12 weeks in previously untreated genotype 1 chronic hepatitis C patients.

Read more:

EASL 2011: Tegobuvir Works Well in Triple and Quad Regimens for HCV

Gilead's HCV polymerase inhibitor tegobuvir (GS-9190) improved response rates in treatment-naive genotype 1 patients when used in various combinations with pegylated interferon, ribavirin, and the experimental protease inhibitor GS-9256, researchers reported at EASL 2011.

Read more: